ArticleCancer management and research2025
Blood Stasis Constitution Ointment Exerts Anti-Lung Cancer Effects: A Study Integrating Network Pharmacology, Transcriptomics, and Experimental Validation.
Article in Cancer management and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim of the Study: To analyze the chemical components of BSCO, evaluate its effects on lung cancer through vivo and vitro experiments, reveal its underlying mechanism in a rat model of LC. Methods: Ultra-high performance liquid chromatography with quadrupole time-of-flight mass spectrometry was used to identify components of BSCO. A Lewis lung cancer model was established in mice to evaluate the effects of BSCO by observing tissue morphology, whole animal imaging, and determination of serum biochemical indicators. The effects of BSCO on Lewis cancer cells in vitro were assessed using a CCK-8 cell proliferation assay. Network pharmacology and transcriptomics analysis was used to predict their targets and signaling pathways associated with lung cancer. The mRNA expressions of target genes were measured by RT-qPCR. Results: Twenty major chemical components of BSCO were identified. BSCO effectively inhibited tumor growth in the Lewis lung cancer mouse model and normalized serum markers of cancer to varying degrees. The IC Conclusion: BSCO significantly inhibited lung cancer growth in vitro and in vivo. Network pharmacology and transcriptomics suggested that its anti-cancer effects might involve the PI3K-Akt signaling pathway, TP53, IL6, CDKN1A, and KIT may be its key targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.